These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25573676)

  • 1. Treatment of Clostridium difficile infections.
    Soriano MM; Johnson S
    Infect Dis Clin North Am; 2015 Mar; 29(1):93-108. PubMed ID: 25573676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
    Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Individualized treatment strategies for Clostridium difficile infections].
    Solbach P; Dersch P; Bachmann O
    Internist (Berl); 2017 Jul; 58(7):675-681. PubMed ID: 28589214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clostridium difficile colitis: review of the therapeutic approach.
    Joseph J; Singhal S; Patel GM; Anand S
    Am J Ther; 2014; 21(5):385-94. PubMed ID: 22990077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
    Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
    J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and management of Clostridium difficile infection.
    Dupont HL
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and opportunities in the management of Clostridium difficile infection.
    DuPont HL
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):863-74. PubMed ID: 25012255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?
    Manthey CF; Eckmann L; Fuhrmann V
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1239-1250. PubMed ID: 28766951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
    Venugopal AA; Johnson S
    Clin Infect Dis; 2012 Feb; 54(4):568-74. PubMed ID: 22156854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
    Tannock GW; Munro K; Taylor C; Lawley B; Young W; Byrne B; Emery J; Louie T
    Microbiology (Reading); 2010 Nov; 156(Pt 11):3354-3359. PubMed ID: 20724385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of Clostridium difficile treatments: a systematic review.
    Drekonja DM; Butler M; MacDonald R; Bliss D; Filice GA; Rector TS; Wilt TJ
    Ann Intern Med; 2011 Dec; 155(12):839-47. PubMed ID: 22184691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fidaxomicin, a new treatment for Clostridium difficile infections.
    Epstein L; Golan Y
    Drugs Today (Barc); 2012 Feb; 48(2):101-8. PubMed ID: 22384450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.